ImmunoGen, Gilead To Evaluate Pivekimab With Magrolimab In R/R CD123-positive Acute Myeloid Leukemia

ImmunoGen, Inc. (IMGN) announced a clinical collaboration with Gilead Sciences, Inc. (GILD) to evaluate the safety and anti-leukemia activity of pivekimab sunirine in combination with magrolimab in patients with relapsed or refractory CD123-positive acute myeloid leukemia. The collaboration will be a new cohort in ImmunoGen's 802 study and will evaluate pivekimab in combination with magrolimab in up to 42 patients with R/R CD123-positive acute myeloid leukemia.

Magrolimab is a potential, first-in-class, investigational treatment designed to inhibit the CD47 protein.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. reported Wednesday weak profit in its fourth quarter, while adjusted EBITDA surged from last year with strong revenue growth above market view. Gross bookings increased and the company projects higher gross bookings in the first quarter. Nelson Chai, CFO, said the company significantly exceeded profitability outlook in 2022, ... Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats.
Follow RTT